ATE232867T1 - Tetronsäurederivate zur behandlung von hiv- und anderen retroviruserkrankungen - Google Patents

Tetronsäurederivate zur behandlung von hiv- und anderen retroviruserkrankungen

Info

Publication number
ATE232867T1
ATE232867T1 AT96911227T AT96911227T ATE232867T1 AT E232867 T1 ATE232867 T1 AT E232867T1 AT 96911227 T AT96911227 T AT 96911227T AT 96911227 T AT96911227 T AT 96911227T AT E232867 T1 ATE232867 T1 AT E232867T1
Authority
AT
Austria
Prior art keywords
treatment
tetronsic
hiv
pct
acid derivatives
Prior art date
Application number
AT96911227T
Other languages
English (en)
Inventor
Robert A Chrusciel
Linda Louise Maggiora
Suvit Thaisrivongs
James Michael Tustin
Clark William Smith
Ruben Tommasi
Paul Adrian Aristoff
Harvey Irving Skulnick
W Jeffrey Howe
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Application granted granted Critical
Publication of ATE232867T1 publication Critical patent/ATE232867T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/60—Two oxygen atoms, e.g. succinic anhydride
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT96911227T 1995-03-20 1996-03-07 Tetronsäurederivate zur behandlung von hiv- und anderen retroviruserkrankungen ATE232867T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40732295A 1995-03-20 1995-03-20
PCT/US1996/002680 WO1996029333A1 (en) 1995-03-20 1996-03-07 Substituted tetronic acids useful for treating hiv and other retroviruses

Publications (1)

Publication Number Publication Date
ATE232867T1 true ATE232867T1 (de) 2003-03-15

Family

ID=23611540

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96911227T ATE232867T1 (de) 1995-03-20 1996-03-07 Tetronsäurederivate zur behandlung von hiv- und anderen retroviruserkrankungen

Country Status (11)

Country Link
US (1) US6060600A (de)
EP (1) EP0817786B1 (de)
JP (1) JPH11503416A (de)
AT (1) ATE232867T1 (de)
AU (1) AU5417696A (de)
DE (1) DE69626276T2 (de)
DK (1) DK0817786T3 (de)
ES (1) ES2191095T3 (de)
PT (1) PT817786E (de)
SI (1) SI0817786T1 (de)
WO (1) WO1996029333A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9603097D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline compounds
JP3726684B2 (ja) * 2001-01-11 2005-12-14 株式会社Kddi研究所 動画像データ転送における輻輳を回避する通信システム
DE102006039912A1 (de) * 2006-08-25 2008-03-20 Bayer Healthcare Ag Substituierte Spirotetronsäuren und ihre Verwendung
DE102006059319A1 (de) * 2006-12-15 2008-06-19 Bayer Healthcare Ag Substituierte Aminofuranone und ihre Verwendung

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA852614B (en) * 1985-05-17 1986-10-09 Takeda Chemical Industries, Ltd. Ascorbic acid ethers and their production
JP2515556B2 (ja) * 1986-08-29 1996-07-10 武田薬品工業株式会社 ヒドロキシブテノライド誘導体およびその製造法
KR970005488B1 (ko) * 1988-10-20 1997-04-16 시오노 기세이야꾸 가부시끼가이샤 항생제 pb-6042류
JP3156006B2 (ja) * 1990-07-30 2001-04-16 武田薬品工業株式会社 テトロン酸誘導体、その製造法及び用途
EP0480624A1 (de) * 1990-10-11 1992-04-15 Merck & Co. Inc. HIV Protease Hemmstoffe
AU2267992A (en) * 1991-08-27 1993-03-16 Upjohn Company, The Compounds used for the inhibition of hiv-protease
DE69226487T2 (de) * 1991-09-26 1999-02-18 Nippon Zoki Pharmaceutical Co., Ltd., Osaka Verwendung von Furanonderivaten zur Vorbeugung oder Behandlung von Autoimmunkrankheiten
ZA938019B (en) * 1992-11-13 1995-04-28 Upjohn Co Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating HIV and other retroviruses
IL108459A0 (en) * 1993-02-05 1994-04-12 Opjohn Company 4-Hydroxy-benzopyran-2-ones and 4-hydroxy-cycloalkyl [B] pyran-2-ones useful for treating infections due to hiv and other retroviruses
EP0720607A1 (de) * 1993-09-17 1996-07-10 PHARMACIA & UPJOHN COMPANY Substituierte tetronsäuren zur behandlung von hiv und anderen retroviren

Also Published As

Publication number Publication date
DE69626276T2 (de) 2003-11-13
PT817786E (pt) 2003-06-30
JPH11503416A (ja) 1999-03-26
WO1996029333A1 (en) 1996-09-26
ES2191095T3 (es) 2003-09-01
US6060600A (en) 2000-05-09
DE69626276D1 (de) 2003-03-27
DK0817786T3 (da) 2003-05-26
EP0817786B1 (de) 2003-02-19
SI0817786T1 (en) 2003-08-31
EP0817786A1 (de) 1998-01-14
AU5417696A (en) 1996-10-08

Similar Documents

Publication Publication Date Title
EE03969B1 (et) (Metüülsulfonüül)fenüül-2-(5H)-furanoonid, nende kasutamine ja farmatseutilised kompositsioonid
EP0676954A4 (de) Hiv-lockvirus.
ATE262336T1 (de) Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa- 4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14- dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen
EA200100524A1 (ru) Амиды антраниловой кислоты и их применение в качестве лекарственных средств
DE3772429D1 (de) Pharmazeutisches praeparat zur behandlung von peridontalkrankheiten.
BR9812837A (pt) Processo para fazer um composto, e, composto
ATE200669T1 (de) 4-hydroxy-benzopyran-2-one und 4-hydroxy- zykloalkyl(b) - pyran--2-one verwendbarfuer die behandlung von retroviralen infectionen
DE69427344D1 (de) Verabreichung von riluzol zur behandlung von neuro-aids
BR9509975A (pt) Formulação farmacêutica
ATE78696T1 (de) Arzneimittelzubereitung zur behandlung des immunmangels.
DE68904462D1 (de) 4-chinolincarbonsaeure-derivate, brauchbar zur behandlung von haut- und muco-epithelial-gewebekrankheiten.
ES2132383T3 (es) Inhibidores de proteasa hiv.
DE69805305D1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
ATE223721T1 (de) Edelfosin zur behandlung von hirntumoren
DE69626276D1 (de) Tetronsäurederivate zur behandlung von hiv- und anderen retroviruserkrankungen
HUP0103712A2 (hu) Paroxetin sók, eljárás az előállításukra és gyógyászati alkalmazásuk
DE69522702D1 (de) Eine lagerstabile wässrige lösung zur infusion die einen thrombininhibitor enthält
ATE197545T1 (de) Verwendung von aspirin zur herstellung eines arzneimittels zur verbesserung fer blutperfusion des uterus
DE69621786D1 (de) Aminotetralinderivat zur behandlung von herzkreislauferkrankung
ATE383161T1 (de) Kombination von product r mit einem antiviralen mittel in der behandlung von hiv infektionen
ATE190484T1 (de) Arzneimittel zur behandlung von durch babesia verursachten protozoeninfektionen
IL117083A0 (en) Pyridine and pyridazine derivatives processes for the production thereof and pharmaceutical agents containing these compounds
DE68903930D1 (de) Lipidemulsion zur behandlung von aids.
FR2613621B1 (fr) Butyl hydroxyanisoles pour utilisation dans le traitement prophylactique des maladies a retro-virus comme agents modificateurs de l'infectivite des retro-virus et produits anti-infectants
SE9404438D0 (sv) New process

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0817786

Country of ref document: EP

REN Ceased due to non-payment of the annual fee